CN101978949A - Gamma-linolenate fat emulsion intravenous injection and preparation method thereof - Google Patents
Gamma-linolenate fat emulsion intravenous injection and preparation method thereof Download PDFInfo
- Publication number
- CN101978949A CN101978949A CN 201010545130 CN201010545130A CN101978949A CN 101978949 A CN101978949 A CN 101978949A CN 201010545130 CN201010545130 CN 201010545130 CN 201010545130 A CN201010545130 A CN 201010545130A CN 101978949 A CN101978949 A CN 101978949A
- Authority
- CN
- China
- Prior art keywords
- gamma
- linolenic acid
- fat emulsion
- acid ester
- linolenate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides gamma-linolenate fat emulsion intravenous injection and a preparation method thereof. The preparation method comprises the following steps of: mixing raw materials such as gamma-linolenate, lecithin, glycerin, sterile pure water, an antioxidant, a stabilizer, a pH regulator and the like under the protection of nitrogen, violently stirring and shearing at a high speed to form primary emulsion; and emulsifying by using a high-pressure homogenizer, filtering by using a microporous membrane filter, filling, sealing and sterilizing to obtain the gamma-linolenate fat emulsion intravenous injection, wherein the gamma-linolenate is gamma-methyl linolenate, gamma-ethyl linolenate, gamma-ethylene linolenate, gamma-propylene linolenate or gamma-triglyceride linolenate, and the gamma-linolenic acid content of the injection is over 90 percent. The gamma-linolenate fat emulsion intravenous injection is used for the fields of medical treatment and health and can be used as a nutritional and therapeutic medicament through abenteric intravenous injection administration, intestinal tube feeding or oral administration.
Description
Technical field
The invention belongs to field of medicaments, relate to a kind of gamma-Linolenic acid, make gamma-Linolenic acid through the fat emulsion intravenous fluid injection through fat emulsion intravenous fluid injection and manufacture method thereof, outer for intestinal through intravenous administration; Or supply enteral through tube feed or oral administration.This gamma-Linolenic acid ester fat emulsion intravenous fluid injection is used for the treatment of diseases such as heart disease, angiopathy, hypertension, diabetes, obesity, premenstrua syndrome and optimum mastopathy, alzheimer disease.
Background technology
Gamma-Linolenic acid (Gamma – Linolenic acid, GLA), the common name isolenic acid, vitaminF, formal name used at school: all-cis 6,9, (Gamma-6 for the 12-jeceric acid, 9,12 ,-octadecatrienoic acid), belong to ω-6 class polyunsaturated fatty acid, there are three conjugated double bonds in the gamma-Linolenic acid molecule, so very strong reproducibility is arranged.
Gamma-Linolenic acid and arachidonic acid then can pass through to synthesize after the linoleic acid dehydrogenation, though gamma-Linolenic acid has the important physical activity, are not essential fatty acid, can transform synthetic in the human body.
In natural oil, according to the difference of the nearest double-linked carbon number of polyunsaturated fatty acid methyl end distance unsaturated fatty acid is divided into 3 series: based on ω-9 series of oleic acid; ω-6 series based on linoleic acid, gamma-Linolenic acid, arachidonic acid; Based on ω-3 series of alpha-linolenic acid, EPA, DHA, the fatty acid of these 3 series can not transform in vivo mutually.Alpha-linolenic acid belongs to ω-3 series, and gamma-Linolenic acid belongs to ω-6 series, and belonging to linolenic alpha-linolenic acid and gamma-Linolenic acid together all is jeceric acid, and the two belongs to isomers, and difference only is the position difference of one of them two key.The two chemical constitution there are differences, and causes both metabolism and physiological function in vivo to there are differences.
The living resources of gamma-Linolenic acid mainly contain plant resources and microbial resources two parts.Gamma-Linolenic acid mainly is distributed in higher plant Oenotheraceae (Onagraceae), Boraginaceae (Boraginaceae), Scrophulariaceae (Sccrophulariaceae), Saxifragaceae (Saxifragaceae) etc. in the plant resources.
Gamma-Linolenic acid finds from Radix Oenotherae erythrosepalae that at first containing ratio is between 23 ~ 30% in the Radix Oenotherae erythrosepalae, and gamma-linolenic acid content is between 8% ~ 10%.Contain gamma-Linolenic acid about 11% in black currant (the Ribes nigrum L.) oil; The Pinus armandi Franch-P. Komavovii Lavl. of China's special product (PinusArmandiFranch) seed oil content is 51.2%, gamma-linolenic acid content is 37.93%, in China Qinghai-Tibet and micropore grass (Microula Sikkimensis Hemsli) the oil content 40%-50% that distributes of neighbouring area, gamma-Linolenic acid is 21% ~ 25% in the gamma-Linolenic acid 8.1%, borage (Borago.Offieinalis).
The microbial resources of gamma-Linolenic acid mainly are meant microalgae and fungus, microalgae is the original Producer of polyunsaturated fatty acid in the ocean, the Onacls Cement company biological study institute of Japan and Tokyo agricultural technology university bioengineering dept are united Lan Sizao in the fresh seawater (Spirulina platensis) and chlorella (Chlorella) are carried out illumination cultivation acquisition gamma-Linolenic acid, and its content is respectively 26.25% and 10% of total fatty acid content.People have also had been found that the greasy mushroom of a series of product gamma-Linolenic acids, comprise Mortierella, Rhizopus, Cunninghammella etc.
Gamma-Linolenic acid is a structural material of forming each tissue biological's film of human body, also is the precursor of synthesis of prostaglandins.As the required unsaturated fatty acid of human body metabolism, adult's daily requirement amount is about 36mg/kg.As the intake deficiency, or transform inadequately in the body, can cause the disorder of function in the body, cause some disease, as diabetes, hyperlipidemia etc.
The major physiological effect of gamma-Linolenic acid:
1. tangible blood fat reducing, hypotensive activity are arranged, and its effect for reducing blood fat is more remarkable than linoleic acid;
2. antiinflammatory antiinflammation can prevent and treat allergic dermatitis;
3. has the effect that significantly weakens peroxide injury;
4. prevention alzheimer disease;
5. be used for the dry-out phenomenon that cosmetics then can improve skin, produce lubricated comfortable effect;
6. the premenstrua syndrome there is certain curative effect.
Medically gamma-Linolenic acid is mainly used in diseases such as treatment heart disease, angiopathy, hypertension, diabetes, obesity, premenstrua syndrome and optimum mastopathy, alzheimer disease.
So therefrom be not difficult to find out, replenish gamma-Linolenic acid, not makeup energy simply, the more important thing is and replenish required living matter in the human body, to safeguard the body metabolism balance, prevention and treatment disease.
The purpose of this invention is to provide a kind of is the fat emulsion intravenous fluid injection and the manufacture method of main component with the gamma-Linolenic acid, its gamma-linolenic acid content〉more than 90%.Be used to prevent and treat the disease that the shortage because of the gamma-Linolenic acid essential fatty acid causes.
So therefrom be not difficult to find out, replenish gamma-Linolenic acid, not makeup energy simply, the more important thing is and replenish essential living matter in the human body, to safeguard the body metabolism balance, prevention and treatment disease.
The purpose of this invention is to provide a kind of gamma-Linolenic acid ester fat emulsion intravenous fluid injection and manufacture method, it is gamma-Linolenic acid that said preparation mainly contains effective constituent, its content〉more than 90%, be used for prevention and diseases such as treatment heart disease, angiopathy, hypertension, diabetes, obesity, premenstrua syndrome and optimum mastopathy, alzheimer disease.
Summary of the invention
The object of the invention provides a kind of gamma-Linolenic acid ester fat emulsion intravenous fluid injection and manufacture method.
Gamma-Linolenic acid derives from the seed seed of Radix Oenotherae erythrosepalae of Oenotheraceae Oenothera Radix Oenotherae erythrosepalae (Oenothera biennis); Pinus armandi Franch-P. Komavovii Lavl. (PinusArmandiFranch) seed; Micropore grass (Microula Sikkimensis Hemsli) seed; Borage (Borago.Offieinalis) seed, microalgae and fungus such as spirulina (Spirulina) have another name called cyanophyceae, are refined into buttery oils and fats after hot and cold squeezing extraction or conventional solvent extraction or supercritical CO 2 extraction,
This oils and fats therefrom extracts preparation unsaturated fatty acid and saturated fat acid blend with saponification method, close the bag method through high pressure chromatography, silver nitrate legitimate network, carbamide, lipase concentration method, methods such as vacuum molecular distillation method, separation and purification gets gamma-Linolenic acid, its gamma-linolenic acid content〉more than 90%.
The high-load gamma-Linolenic acid of gained, again through and methanol, ethanol, ethylene glycol, or propylene glycol, or glycerol (glycerol) carries out esterification, make the gamma-Linolenic acid methyl ester respectively, gamma-ethyl linolenate, gamma-Linolenic acid second diester, gamma-Linolenic acid propylene diester, gamma-Linolenic acid triglyceride.
The gamma-Linolenic acid ester that gamma-Linolenic acid ester fat emulsion intravenous fluid injection is used is the gamma-Linolenic acid methyl ester, gamma-ethyl linolenate, gamma-Linolenic acid second diester, gamma-Linolenic acid propylene diester, gamma-Linolenic acid triglyceride a kind of or several.
The preparation of gamma-Linolenic acid ester fat emulsion intravenous fluid injection is with above-mentioned gamma-Linolenic acid ester, with emulsifying agent, after the emulsifying of sterile pure water process high pressure homogenization technique, the gamma-Linolenic acid ester is made chylomicron, the gamma-Linolenic acid ester fat emulsion intravenous fluid injection of making, with the submicron form, with new way directly and easily, by the outer intravenous injection of intestinal, enter blood circulation through intravenous injection, directly by body or cell institute digestibility and utilization, the shortage that prevents and correct the body essential fatty acid, correct fast the body metabolism balance, the disease that prevention and treatment cause because of the shortage of gamma-Linolenic acid essential fatty acid.
Gamma-Linolenic acid ester fat emulsion intravenous fluid injection prescription is: every 1000ml fat emulsion intravenous fluid injection contains gamma-Linolenic acid ester 5-50%, emulsion 1.0-15.0%, isoosmotic adjusting agent 1.0-5.0%, antioxidant 0.01-0.5%, stabilizing agent 0.1-10%, it is 6.5-8.5 that lipomul pH is transferred in the pH regulator agent, and all the other are sterile pure water.
Used gamma-Linolenic acid ester, its content is more than 90%
Gamma-Linolenic acid ester fat emulsion intravenous fluid injection preparation technology flow process is:
A) under nitrogen protection, the gamma-Linolenic acid ester is heated to 70-90 ℃, stir the adding emulsifying agent and form oil phase liquid until dissolving;
B) with glycerol, antioxidant, stabilizing agent, join in the aseptic pyrogen-free sterile pure water, stirring and dissolving forms water liquid;
C) under nitrogen protection, in the intensively stirred water liquid of the slow adding of oil phase liquid, strong agitation forms colostric fluid;
D), regulate the pH to 6.5-8.5 of colostric fluid with a spot of pH regulator agent;
E) use high pressure homogenizer under the pressure of 500-25000psi, with colostrum emulsifying repeatedly, the granularity of prepared fat milk is less than 2 microns.Its average particle size range is the 20-500 nanometer;
F) with the fats emulsion behind the homogenizing through the filtration sterilization of 0.22-0.8 micron microporous membrane filters, under aseptic GMP clean environment, quantitatively pour in the transfusion package container (glass bottle, mould bottle, PVC bag, non-PVC bag), seal behind the inflated with nitrogen;
G) the fat milk goods with packing place in the transfusion steriliser, and 110-121 ℃ of high pressure moist heat sterilization 15-30 minute, F0 value promptly got final gamma-Linolenic acid ester fat emulsion intravenous fluid injection products in 10-16 minute.
The specific embodiment
Below the present invention is described, but the present invention is limited in the example not exclusively by concrete case study on implementation.
Embodiment one,
Prescription: refining gamma-ethyl linolenate 200g, medicinal lecithin 12g, medicinal glycerin 21g, medicinal vitamin E 0.5g, the sodium hydroxide thin liquid is an amount of, and water for injection adds to 1000ml.
1, preparation oil phase liquid: get the refining gamma-ethyl linolenate of formula ratio, medicinal lecithin and medicinal vitamin E, under nitrogen protection, be heated to 80 ℃ of stirrings and make that to be dissolved into oil phase liquid standby;
2, preparation water liquid: getting the medicinal glycerin of formula ratio and water for injection, to be stirred into water liquid standby;
3, first emulsion: under nitrogen protection, under water liquid high-speed stirred, lentamente oil phase liquid is splashed into water liquid, after dripping off, use the high speed shear agitator, first emulsifying 15 minutes;
4, regulate pH: under agitation, transfer pH7.4, and add water for injection to the full dose of filling a prescription with dilute sodium hydroxide water liquid;
5, emulsifying: utilize the high pressure homogenization machine with colostric fluid homogenizing repeatedly, adjusting pressure is 15000psi, and homogenizing 3-6 time is in the fat milk particle diameter is the 100-400nm scope;
6, filter fill: fats emulsion behind the filtering with microporous membrane in 0.6 μ m aperture, is poured in the 250ml infusion bottle (bag), fill nitrogen, sealing;
7, sterilization: place the rotary steam Sterilization Kettle to sterilize the fats emulsion of filling and sealing, sterilized F0 value 15 minutes 30 minutes for 121 ℃.Promptly get final gamma-ethyl linolenate fat emulsion intravenous fluid injection products.
Embodiment two,
Prescription: gamma-Linolenic acid propylene diester 200g, medicinal lecithin 8g, poloxamer 5g, medicinal glycerin 20g, hydroxy propyl-Beta-cyclodextrin 2g, hydroxypropyl emthylcellulose 3g, the sodium acetate thin liquid is an amount of, and water for injection adds to 1000ml.
1, preparation oil phase liquid: get the medicinal gamma-Linolenic acid propylene diester of formula ratio, add medicinal lecithin, poloxamer, under nitrogen protection, be heated to 80 ℃ of stirrings and make that to be dissolved into oil phase liquid standby;
2, preparation water liquid: after hydroxy propyl-Beta-cyclodextrin, the hydroxypropyl emthylcellulose of getting formula ratio added the water for injection stirring and dissolving, adding medicinal glycerin again, to be stirred into water liquid standby;
3, first emulsifying: under nitrogen protection, under water liquid high-speed stirred, lentamente oil phase liquid is splashed into water liquid, after dripping, use the high speed shear agitator, first emulsifying 15 minutes;
4, regulate pH: under agitation, transfer pH8.0, and add water for injection to the full dose of filling a prescription with dilute sodium hydroxide water liquid;
5, emulsifying: utilize the high pressure homogenization machine with colostric fluid homogenizing repeatedly, adjusting pressure is 15000psi, and homogenizing 3-6 time is in the fat milk particle diameter is the 100-400nm scope;
6, aseptic filtration fill: operate under the gnotobasis condition, emulsion behind the filtering with microporous membrane in 0.22 μ m aperture, is poured in the 250ml non-PVC-soft-bag, fill nitrogen, sealing promptly gets final gamma-Linolenic acid propylene diester fat emulsion intravenous fluid injection products.
Embodiment three,
Prescription: gamma-Linolenic acid triglyceride 200g, medicinal lecithin 13g, medicinal glycerin 18g, hydroxy propyl-Beta-cyclodextrin 5g, the sodium hydroxide thin liquid is an amount of, and water for injection adds to 1000ml.
1, preparation oil phase liquid: get the medicinal refining gamma-Linolenic acid triglyceride and the medicinal lecithin of formula ratio, under nitrogen protection, be heated to 80 ℃ of stirrings and make that to be dissolved into oil phase liquid standby;
2, preparation water liquid: after hydroxy propyl-Beta-cyclodextrin of getting formula ratio added the water for injection stirring and dissolving, adding medicinal glycerin again, to be stirred into water liquid standby;
3, first emulsifying: under nitrogen protection, under water liquid high-speed stirred, lentamente oil phase liquid is splashed into water liquid, after dripping, use the high speed shear agitator, first emulsifying 15 minutes;
4, regulate pH: under agitation, transfer pH8.0, and add water for injection to the full dose of filling a prescription with dilute sodium hydroxide water liquid;
5, emulsifying: utilize the high pressure homogenization machine with colostric fluid homogenizing repeatedly, adjusting pressure is 15000psi, and homogenizing 3-6 time is in the fat milk particle diameter is the 100-400nm scope;
6, filter fill: emulsion behind the filtering with microporous membrane in 0.6 μ m aperture, is poured in the 250ml infusion bottle, fill nitrogen, sealing,
7, sterilization: place the rotary steam Sterilization Kettle to sterilize the fats emulsion of filling and sealing, sterilized F0 value 15 minutes 30 minutes for 121 ℃.Promptly get final gamma-Linolenic acid fat of triglyceride milk vein injection products.
Claims (10)
1. gamma-Linolenic acid ester fat emulsion intravenous fluid injection, it is characterized in that this prescription is: every 1000ml gamma-Linolenic acid ester fat emulsion intravenous fluid injection contains refining gamma-Linolenic acid ester 5-50%, emulsifying agent 1.0-15.0%, fats emulsion pH to 6.5-8.5 is transferred in isoosmotic adjusting agent 1.0-5.0%, antioxidant 0.01-0.5%, stabilizing agent 0.1-10%, pH regulator agent, and all the other are sterile pure water.
2. gamma-Linolenic acid ester fat emulsion intravenous fluid injection according to claim 1 is characterized in that described gamma-Linolenic acid ester derives from:
(a) the seed seed of Radix Oenotherae erythrosepalae of Oenotheraceae Oenothera Radix Oenotherae erythrosepalae (Oenothera biennis); Pinus armandi Franch-P. Komavovii Lavl. (PinusArmandiFranch) seed; Micropore grass (Microula Sikkimensis Hemsli) seed; Borage (Borago.Offieinalis) seed; Microalgae and fungus such as spirulina (Spirulina) have another name called cyanophyceae, are refined into buttery oils and fats after hot and cold squeezing extraction or conventional solvent extraction or supercritical CO 2 extraction;
(b) this oils and fats therefrom extracts preparation unsaturated fatty acid and saturated fat acid blend with saponification method, close the bag method through high pressure chromatography, silver nitrate legitimate network, carbamide, lipase concentration method, methods such as vacuum molecular distillation method, separation and purification gets gamma-Linolenic acid, its gamma-linolenic acid content〉more than 90%;
(c) the highly purified gamma-Linolenic acid of gained again through and methanol, ethanol, ethylene glycol, propylene glycol, glycerol (glycerol) carries out esterification, get the gamma-Linolenic acid methyl ester, gamma-ethyl linolenate, gamma-Linolenic acid second diester, gamma-Linolenic acid propylene diester, gamma-Linolenic acid triglyceride;
(d) the used gamma-Linolenic acid methyl ester of gamma-Linolenic acid ester fat emulsion intravenous fluid injection, gamma-ethyl linolenate, gamma-Linolenic acid second diester, gamma-Linolenic acid propylene diester, gamma-Linolenic acid triglyceride a kind of or several.
3. gamma-Linolenic acid ester fat emulsion intravenous fluid injection according to claim 1 is characterized in that described emulsifying agent is a kind of or several in refined lecithin, soybean lecithin, Ovum Gallus domesticus Flavus lecithin, poloxamer, polyethyleneglycol glyceride, the polyoxyethylene methyl Oleum Ricini ether.
4. gamma-Linolenic acid ester fat emulsion intravenous fluid injection according to claim 1 is characterized in that described isoosmotic adjusting agent is a kind of or several in glycerol, sorbitol, the manna alcohol and glucose.
5. gamma-Linolenic acid ester fat emulsion intravenous fluid injection according to claim 1 is characterized in that described antioxidant is one or more in vitamin E, vitamin C, sodium sulfite, the disodium edetate.
6. gamma-Linolenic acid ester fat emulsion intravenous fluid injection according to claim 1 is characterized in that described stabilizing agent is one or more in hydroxy propyl-Beta-cyclodextrin, Polyethylene Glycol, polyvinylpyrrolidone, hydroxypropyl emthylcellulose, the oligomeric generation hydroxypropyl cellulose.
7. gamma-Linolenic acid ester fat emulsion intravenous fluid injection according to claim 1, it is characterized in that described pH regulator agent is one or more mixing materials in hydrochloric acid, sodium hydroxide, phosphoric acid, phosphate, citric acid, citrate, acetic acid, the acetate, regulate linseed oil fat emulsion intravenous fluid pH scope at 6.5-8.5.
8. gamma-Linolenic acid ester fat emulsion intravenous fluid injection according to claim 1 is characterized in that described preparation technology is:
(a) under nitrogen protection, will make with extra care the gamma-Linolenic acid ester and be heated to 70-90 ℃, stir the adding emulsifying agent and form oil phase liquid until dissolving;
(b) with glycerol, antioxidant, stabilizing agent, join in the aseptic pyrogen-free sterile pure water, stirring and dissolving forms water liquid;
(c) under nitrogen protection, in the intensively stirred water liquid of the slow adding of oil phase liquid, strong agitation forms colostric fluid;
(d), regulate the pH to 6.5-8.5 of colostric fluid with a spot of pH regulator agent;
(e) use high pressure homogenizer under the pressure of 500-25000psi, with colostrum emulsifying repeatedly, the granularity of prepared fats emulsion is less than 2 microns, and its average particle size range is the 20-500 nanometer;
(f) with the fats emulsion behind the homogenizing through the filtration sterilization of 0.22-0.8 micron microporous membrane filters, in aseptic GMP clean environment, quantitatively pour in the transfusion package container (glass bottle, mould bottle, PVC bag, non-PVC bag), seal behind the inflated with nitrogen;
(g) the fats emulsion goods of package encapsulation are placed in the transfusion steriliser, 110-121 ℃ of high pressure moist heat sterilization 15-30 minute,
The F0 value promptly got final gamma-Linolenic acid ester fat emulsion intravenous fluid injection products in 10-16 minute.
9. gamma-Linolenic acid ester fat emulsion intravenous fluid injection according to claim 1, it is characterized in that being applied to medical field, is the application that is used for the treatment of prevention, treatment and the nutritional supplementation of multiple diseases such as heart disease, angiopathy, hypertension, diabetes, obesity, premenstrua syndrome and optimum mastopathy, alzheimer disease.
10. gamma-Linolenic acid ester fat emulsion intravenous fluid injection according to claim 1 is characterized in that making gamma-Linolenic acid ester fat emulsion intravenous fluid injection, and is outer through intravenous administration for intestinal; Or supply enteral through tube feed or oral administration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010545130 CN101978949A (en) | 2010-11-16 | 2010-11-16 | Gamma-linolenate fat emulsion intravenous injection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010545130 CN101978949A (en) | 2010-11-16 | 2010-11-16 | Gamma-linolenate fat emulsion intravenous injection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101978949A true CN101978949A (en) | 2011-02-23 |
Family
ID=43599504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010545130 Pending CN101978949A (en) | 2010-11-16 | 2010-11-16 | Gamma-linolenate fat emulsion intravenous injection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101978949A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016537422A (en) * | 2013-11-12 | 2016-12-01 | ネイチャーセンス カンパニー リミテッド | Composition for improving, preventing or treating metabolic diseases comprising Borage extract |
| US20170196807A1 (en) * | 2014-09-25 | 2017-07-13 | Fujifilm Corporation | Propofol-containing oil-in-water emulsion composition and method for producing same |
| WO2018054265A1 (en) * | 2016-09-20 | 2018-03-29 | 张碧婷 | Hydrophilic lipid composition packaging composition, preparation and blending method for same, and applications thereof |
| CN108553419A (en) * | 2018-05-24 | 2018-09-21 | 安阳工学院 | A kind of Alpha-ethyl linolenate microemulsion and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1091285A (en) * | 1992-08-21 | 1994-08-31 | 斯科舍集团有限公司 | The ester fatty acid treatment |
| CN1166351A (en) * | 1997-05-23 | 1997-12-03 | 北京路德有限责任公司 | Soft antilipemic capsule |
| CN1384089A (en) * | 2002-02-10 | 2002-12-11 | 李景明 | Extract containing rich gamma-linolenic acid and its prepn |
| CN101869602A (en) * | 2010-07-23 | 2010-10-27 | 王京南 | Compound evening primrose and linseed oil fat emulsion intravenous fluid and preparation method |
| CN101879212A (en) * | 2010-07-19 | 2010-11-10 | 王京南 | Compound walnut and linseed oil fat emulsion intravenous injection and preparation method thereof |
-
2010
- 2010-11-16 CN CN 201010545130 patent/CN101978949A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1091285A (en) * | 1992-08-21 | 1994-08-31 | 斯科舍集团有限公司 | The ester fatty acid treatment |
| CN1166351A (en) * | 1997-05-23 | 1997-12-03 | 北京路德有限责任公司 | Soft antilipemic capsule |
| CN1384089A (en) * | 2002-02-10 | 2002-12-11 | 李景明 | Extract containing rich gamma-linolenic acid and its prepn |
| CN101879212A (en) * | 2010-07-19 | 2010-11-10 | 王京南 | Compound walnut and linseed oil fat emulsion intravenous injection and preparation method thereof |
| CN101869602A (en) * | 2010-07-23 | 2010-10-27 | 王京南 | Compound evening primrose and linseed oil fat emulsion intravenous fluid and preparation method |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016537422A (en) * | 2013-11-12 | 2016-12-01 | ネイチャーセンス カンパニー リミテッド | Composition for improving, preventing or treating metabolic diseases comprising Borage extract |
| US20170196807A1 (en) * | 2014-09-25 | 2017-07-13 | Fujifilm Corporation | Propofol-containing oil-in-water emulsion composition and method for producing same |
| WO2018054265A1 (en) * | 2016-09-20 | 2018-03-29 | 张碧婷 | Hydrophilic lipid composition packaging composition, preparation and blending method for same, and applications thereof |
| CN108553419A (en) * | 2018-05-24 | 2018-09-21 | 安阳工学院 | A kind of Alpha-ethyl linolenate microemulsion and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3363431B1 (en) | Method of preparing highly stable microcapsule powder or microparticles containing fat-soluble nutrient having increased double bonds | |
| RU2276975C2 (en) | Therapeutic combinations of fatty acids | |
| JPWO2011118810A1 (en) | Nutritional composition | |
| CN1391464A (en) | Formulation for menopausal women | |
| CN107660620B (en) | Sheep-based oil microcapsule powder and preparation method thereof | |
| JP2019511583A (en) | Coenzyme Q10 solubilized composition and method for producing the same | |
| TW201400110A (en) | Compositions comprising omega-3 fatty acids and vitamin D for acne vulgaris and/or eczema, and methods and uses thereof | |
| CN105476959B (en) | A kind of medium chain triglycerides nano-emulsion and preparation method thereof | |
| CN103190619A (en) | Fish oil and linseed oil soft capsules and preparation method thereof | |
| CN105434331B (en) | A kind of self-emulsifying Co-Q10 finish and its preparation method and application | |
| CN101978949A (en) | Gamma-linolenate fat emulsion intravenous injection and preparation method thereof | |
| CN101167793A (en) | Walnut oil fat emulsion and manufacturing method thereof | |
| CN101194919B (en) | Hippophae rhamnoides seed oil fatty milk injection and technique of preparing the same | |
| JP2022065087A (en) | Preparation and stabilization methods for emulsion having omega-3 by isometric crystal network of cellulose derivative | |
| CN101816423A (en) | Purple perilla seed oil lipid emulsion oral solution, beverage and manufacturing method thereof | |
| CN101978950A (en) | Alpha-linolenic acid ester fat emulsion injection and preparation method thereof | |
| WO2004075878A1 (en) | Fatty emulsion injection of seal oil, method for preparation and the use in manufacturing intravenous injection | |
| CN101797270B (en) | Silkworm pupal oil fat emulsion intravenous fluid and preparation method | |
| CN101869297A (en) | Compound evening primrose and perilla herb oil fat emulsion oral solution, beverage and preparation method | |
| CN102018763A (en) | Linseed oil fat emulsion intravenous injection fluid and production method thereof | |
| CN106031722A (en) | Composition for treating diseases caused by body and nervous system disorder or inflammation, and applications thereof | |
| CN1122528C (en) | Composite safflower oil preparation and medicine containing it | |
| JP2018531251A6 (en) | Method for preparing and stabilizing an emulsion having omega-3 by an equiaxed crystal network of cellulose derivatives | |
| CN101978951A (en) | 9,10-diphenylanthracene(DPA) ester fat emulsion intravenous injection and manufacturing method thereof | |
| CN101879212A (en) | Compound walnut and linseed oil fat emulsion intravenous injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20110223 |